Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-171

This is a transformational result in the treatment of Grade II cardiovascular disease . I would regard the WORST outcome as a massive Phase 3 confirmatory trial with a global Pharma to start in the next 12 months?...with all past costs recovered and favourable royalties. These results showed efficacy is ischemic AND non ischemic. Let the post hoc analysis commence. I think a partnership might provide a valuation of at least $5-10bn.
We must wait for the FDAs reaction to these amazing numbers. I appreciate missing a primary endpoint is normally a disaster but this is a result is even better in the long run,than a reduction in Class 3 non fatal MACE...in my opinion . Silviu’s point about the relevance of surrogate endpoints not mattering when you achieve the gold standard reduction in cv death is the most important one.

Watch the share price turn round when people understand that today is an historic moment . The penny will drop post a view from the FDA about an approval pathway .







Please do not rely on any facts or opinions expressed when making an investment decision. OP